Department of Clinical Laboratory, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou, China.
Clin Chim Acta. 2022 Sep 1;534:138-145. doi: 10.1016/j.cca.2022.07.014. Epub 2022 Jul 26.
Metabolic dysfunction associated fatty liver disease (MAFLD) is the most common liver disease and dyslipidemia is commonly considered a prominent risk factor for MAFLD. This study was to investigate the association between the apolipoprotein B/A1 (apo B/A1) ratio and the risk of MAFLD based on new diagnostic criteria.
We conducted a cross-sectional study on 3341 participants. Restricted cubic spline (RCS) analyses, logistic regression, Synergistic effects analyses and stratified analyses were used to evaluate the association between the apo B/A1 ratio and the risk of MAFLD.
The apo B/A1 ratio was nonlinearly related to the increased risk of MAFLD and the OR and 95% CI for the apo B/A1 95th percentile was 1.700 (1.004-2.879) compared with the 50th percentile. Each 1 SD increase in apo B/A1 ratio would increase the 1.313-fold risk of the risk of MAFLD in all participants and 1.46-fold risk in normolipidemic participants. Synergistic effects indicated elevated Apo B/A1 ratio and dyslipidemia collectively contributed to an increased risk of MAFLD [OR (95 %CI): 2.496(1.869-3.334)].
The apo B/A 1 ratio was a risk factor of the presence of MAFLD. Dyslipidemia and elevated the Apo B/A1 ratio can synergistically contributed to the risk of MAFLD.
代谢相关脂肪性肝病(MAFLD)是最常见的肝脏疾病,血脂异常通常被认为是 MAFLD 的一个突出危险因素。本研究旨在根据新的诊断标准,探讨载脂蛋白 B/A1(apo B/A1)比值与 MAFLD 风险的关系。
我们对 3341 名参与者进行了横断面研究。采用限制性立方样条(RCS)分析、逻辑回归、协同作用分析和分层分析来评估 apo B/A1 比值与 MAFLD 风险之间的关系。
apo B/A1 比值与 MAFLD 风险呈非线性相关,apo B/A1 第 95 百分位数与第 50 百分位数相比,OR 和 95%CI 为 1.700(1.004-2.879)。apo B/A1 比值每增加 1SD,所有参与者中 MAFLD 的风险增加 1.313 倍,血脂正常的参与者中风险增加 1.46 倍。协同作用表明,apo B/A1 比值升高和血脂异常共同导致 MAFLD 的风险增加[OR(95%CI):2.496(1.869-3.334)]。
apo B/A1 比值是 MAFLD 的一个危险因素。血脂异常和升高的 apo B/A1 比值可协同增加 MAFLD 的风险。